Bliss GVS Pharma Peer Comparison

NSE: BLISSGVS | BSE: 506197

₹699.20

₹4.60 (0.66%)

As on 23-Sep-2026IST

Market cap

₹7,411 Cr

Revenue (TTM)

₹1,005 Cr

P/E Ratio

54.4

P/B Ratio

Div. Yield

0.2 %

Edit

	Bliss GVS Pharma	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Market cap (₹ Cr)	7,411	21,217	20,284	17,618	18,377
Revenue (₹ Cr)	1,005	2,287	1,682	3,230	2,570
Net Profit (₹ Cr)	141.74	678.07	273.51	666.92	735.15
Net Margin (%)	13.31	28.10	16.19	20.60	26.88
RoE (%)	11.84	19.73	11.15	18.75	19.16
Price to Earnings	54.42	31.89	68.22	27.36	25.00
Price-To-Book	6.01	5.78	7.55	4.37	4.17

Income Statement (₹ Cr)

	Bliss GVS Pharma	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Operating Revenue	1,005.22	2,287.33	1,682.47	3,229.67	2,569.77
Total Income	1,064.61	2,413.29	1,689.83	3,237.12	2,735.39
Total Expenditure	817.83	1,490.75	1,203.91	2,090.06	1,628.14
EBITDA	187.39	796.58	478.55	1,139.61	941.63
Depreciation	35.22	78.10	126.01	281.06	57.58
EBIT	152.17	718.48	352.55	858.55	884.05
Interest	7.12	0.88	52.11	190.64	7.69
Other Income	59.40	125.96	7.37	7.45	165.62
Exceptional Items	-2.49	0.00	12.16	-17.24	-49.16
Profit before Tax	201.96	843.56	319.96	658.12	992.82
Provision for Tax	60.22	165.49	46.45	-8.80	257.67
Profit after Tax	141.74	678.07	273.51	666.92	735.15

	Bliss GVS Pharma	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Shareholder's Funds	1,192.90	3,586.42	2,591.20	3,902.67	4,202.90
Minority Interest	-5.55	-12.71	0.00	-21.81	0.00
Non-Current Liabilities	25.11	28.74	266.35	1,392.75	91.50
Current Liabilities	235.54	385.94	848.06	2,077.10	627.48
Total Liabilities	1,492.41	4,037.51	3,705.61	7,246.72	4,921.88

	Bliss GVS Pharma	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Non-Current Assets	485.16	1,291.22	2,525.44	5,617.77	770.28
Current Assets	946.34	2,585.66	1,109.77	1,539.85	3,803.22
Total Assets	1,492.41	4,037.51	3,705.61	7,246.72	4,921.88
Total Debt*	2.93	0.57	657.97	2,309.68	2.50
Net Current Assets	710.80	2,199.72	261.71	-537.25	3,175.74
Contingent Liabilities	10.71	17.53	160.01	51.57	370.49

	Bliss GVS Pharma	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Cash From Operating Activities	138.72	523.24	342.18	537.99	967.57
Cash Flow from Investing Activities	-38.28	-582.30	-325.92	-369.46	-561.67
Cash from Financing Activities	-89.21	-46.46	13.62	-313.53	-798.31
Net Cash Inflow / Outflow	11.23	-105.52	29.88	-145.00	-392.41

	Bliss GVS Pharma	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
ROCE (%)	17.40	24.97	11.43	14.47	23.39
ROE (%)	11.84	19.73	11.15	18.75	19.16
ROA (%)	10.15	18.69	7.80	9.26	14.95
EBIT Margin (%)	15.14	31.41	20.95	26.58	34.40
Net Margin (%)	13.31	28.10	16.19	20.60	26.88
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Bliss GVS Pharma	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Revenue Growth (%)	20.59	15.01	27.91	9.59	10.69
EBIT Growth (%)	50.40	18.45	58.32	16.84	24.14
Net Profit Growth (%)	25.98	19.61	149.56	62.68	-9.09
EPS Growth (%)	28.44	17.73	-3.57	67.41	14.40
Book Value Growth (%)	13.14	26.75	9.67	36.71	-0.34

	Bliss GVS Pharma	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Price / Earnings	53.62	31.89	72.37	26.67	23.82
Price / Book Value	6.01	5.78	7.55	4.37	4.17
Dividend Yield (%)	0.22	0.29	0.06	0.00	1.87
EV/EBITDA	38.66	25.37	43.67	17.43	16.22
Market Cap (₹ Cr)	2,280.33	11,439.22	6,819.66	17,980.08	21,592.90

	Bliss GVS Pharma	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debt to Equity	0.00	0.00	0.07	0.24	0.00
Short term debt to equity ratio	0.00	0.00	0.16	0.12	0.00
Current Ratio	4.02	6.70	1.31	0.74	6.06
Quick Ratio	3.38	5.59	0.88	0.53	5.31
Interest Coverage	29.39	959.59	7.14	4.45	130.11

	Bliss GVS Pharma	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debtors to sales (%)	51.45	36.10	30.84	21.07	7.07
Asset Turnover	0.72	0.63	0.48	0.45	0.52
Receivable days	180.13	121.68	113.81	63.88	26.06
Inventory Days	52.09	63.83	84.76	43.27	65.95
Payable days	75.40	108.28	101.94	151.85	81.01
Cash Conversion Cycle	156.82	77.23	96.62	-44.70	11.00

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.